SAN FRANCISCO -- The investigational selective glucocorticoid receptor modulator relacorilant led to improvements in blood ...

Baxdrostat meets primary and all secondary endpoints in BaxHTN phase III trial in patients with uncontrolled or treatment resistant hypertension: Cambridge, UK Wednesday, July 16, ...

In a new clinical practice guideline, the Endocrine Society advises universal screening of those with hypertension by ...

AstraZeneca AZN reported positive top-line results from a late-stage study evaluating the safety, tolerability and efficacy ...

“Baxdrostat BaxHTN Phase III trials on patients with uncontrolled or treatment-resistant hypertension demonstrated a ...

Researchers found a 30% increased risk of cardiovascular events in patients whose diagnosis was delayed by more than a year ...

A new study examining hypertension medication adherence found that high-tech interventions failed to improve how consistently patients take their blood pressure medications, despite successfully ...

Delayed diagnosis of hypertension after initial elevated BP measurement was tied to lower rates of antihypertensive drug ...

At two doses, baxdrostat demonstrated significant reduction in mean seated systolic BP vs. placebo at 12 weeks among patients ...

AstraZeneca’s $1.3 billion bet on CinCor Pharma and its mid-phase hypertension drug baxdrostat seems to have paid off based ...

LAKE CHARLES, La. (KPLC) - High blood pressure, or hypertension, is often called the silent killer. It can affect anyone, even those who spend their lives helping others stay healthy. One Southwest ...

A new study published in the journal of Hypertension showed that the white matter hyperintensity volume was higher 15 years ...